CMS Opts Not To Define Biosimilars As Generics For Cost-Sharing Policy

CMS reduced what low-income beneficiaries pay for biosimilars to the level of generic drug cost-sharing, but the agency changed how it accomplished that goal in the Part D final rule due to brand drug makers' concerns. The agency initially proposed to include biosimilars in the definition of generic drugs, but instead it lowered the maximum copay for biosimilars and interchangeable biologics to that of generic and preferred multiple-source drugs. "[I]n consideration of the comments received, we are not finalizing our...